Stopping immunotherapy after a good melanoma response
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether it’s safe to stop nivolumab (an immunotherapy) after your melanoma has responded well to initial treatment with ipilimumab plus nivolumab. It may help some people avoid ongoing treatment side effects while still keeping the cancer controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have melanoma that is stage III and cannot be removed by surgery, or melanoma that has spread to other parts of the body
- You already received at least one dose of ipilimumab plus nivolumab as your first treatment, and your team feels maintenance treatment with nivolumab (or pembrolizumab) would be the next step
- Your scan results show tumor shrinkage or complete disappearance (CR/PR), not stable or growing disease
- You can have brain imaging (usually MRI) to check for brain metastases before stopping treatment, and if you had brain metastases before, you must be symptom-free
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests whether patients with stage 3 melanoma that shrinks significantly after initial immunotherapy can safely avoid having all their lymph nodes surgically removed. Instead, only the main affected node is removed for testing.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
Hear when a new Melanoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.